Which medications in the drug class Ophthalmics, VEGF Inhibitors are used in the treatment of Choroidal Neovascularization (CNV)?

Updated: Jan 07, 2019
  • Author: Lihteh Wu, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print
Answer

Ophthalmics, VEGF Inhibitors

Aflibercept intravitreal (Eylea)

A recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1. Inhibits all VEFG isoforms and placental growth factor.

Pegaptanib (Macugen)

Selective VEGF antagonist that promotes vision stability and reduces visual acuity loss and progression to legal blindness. VEGF causes angiogenesis and increases vascular permeability and inflammation, all of which contribute to neovascularization in age-related wet macular degeneration.

Ranibizumab (Lucentis)

Ranibizumab is a recombinant monoclonal antibody Fab designed to bind and inhibit VEGF-A, a protein that is believed to play a critical role in the formation of new blood vessels of exudative ARMD. First approved treatment with visual improvement for exudative ARMD.

Bevacizumab (Avastin)

A nonspecific monoclonal anti-VEGF. Off-label drug with apparent similar efficacy of ranibizumab.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!